Mirtazapina Combix (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, leading to increased release of norepinephrine and serotonin. It also antagonises serotonin 5‑HT2 and 5‑HT3 receptors and histamine H1 receptors, which together enhance mood‑lifting neurotransmission while producing sedative and appetite‑stimulating effects.

The appropriate dose of Mirtazapina Combix is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage adjustments may be needed for elderly patients or those with hepatic impairment.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and consider alternative treatments when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct receptor profile that often results in stronger sedative and appetite‑stimulating effects. It may be preferred when patients experience insomnia or weight loss, but its side‑effect profile differs, requiring individualized selection.

Mirtazapina Combix should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

The medication is taken orally, usually once daily in the evening, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether the tablet should be swallowed whole or with a glass of water.

Serious risks include agranulocytosis or severe neutropenia, hepatic dysfunction, seizures, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of infection, liver problems, or any severe allergic response, and seek medical attention promptly if they occur.

Mirtazapina Combix is contraindicated in individuals who have a known hypersensitivity to mirtazapine or any of its excipients. It should also be avoided in patients currently taking monoamine oxidase inhibitors (MAOIs) or those with a history of severe hepatic impairment without appropriate medical supervision.